Imricor Launches U.S. Commercial Operations with First Hospital Customer
Imricor Medical Systems, Inc. (ASX: IMR) has officially launched its U.S. commercial operations after securing Rady Children’s Hospital–San Diego as the first commercial customer for its NorthStar® interventional magnetic resonance (iMR) mapping and guidance system. The milestone follows recent U.S. FDA clearances for the NorthStar system and Vision-MR® Diagnostic Catheter, including expanded approvals for patients of all ages. Rady Children’s will establish the first U.S. radiation-free cardiac catheterisation program using NorthStar, with plans to expand into electrophysiology and cardiac ablation procedures. The launch also marks the introduction of Imricor Cardiovascular, opening access to more than 250 children's hospitals and over 2,000 adult hospitals across the United States. Several additional hospitals are in the final stages of procurement, with management expecting NorthStar sales to exceed the Company's total European revenue generated during 2025, supporting a significant expansion of its commercial footprint.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Imricor Launches U.S. Commercial Operations with First Hospital Customer
Imricor Medical Systems, Inc. (ASX: IMR) has officially launched its U.S. commercial operations after securing Rady Children’s Hospital–San Diego as the first commercial customer for its NorthStar® interventional magnetic resonance (iMR) mapping and guidance system. The milestone follows recent U.S. FDA clearances for the NorthStar system and Vision-MR® Diagnostic Catheter, including expanded approvals for patients of all ages. Rady Children’s will establish the first U.S. radiation-free cardiac catheterisation program using NorthStar, with plans to expand into electrophysiology and cardiac ablation procedures. The launch also marks the introduction of Imricor Cardiovascular, opening access to more than 250 children's hospitals and over 2,000 adult hospitals across the United States. Several additional hospitals are in the final stages of procurement, with management expecting NorthStar sales to exceed the Company's total European revenue generated during 2025, supporting a significant expansion of its commercial footprint.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au